These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16182220)

  • 1. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer.
    Hsu IC; Cabrera AR; Weinberg V; Speight J; Gottschalk AR; Roach M; Shinohara K
    Brachytherapy; 2005; 4(3):202-6. PubMed ID: 16182220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer.
    Sato M; Mori T; Shirai S; Kishi K; Inagaki T; Hara I
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1002-9. PubMed ID: 18448272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
    Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose-rate brachytherapy for large prostate volumes (> or =50cc)-Uncompromised dosimetric coverage and acceptable toxicity.
    Monroe AT; Faricy PO; Jennings SB; Biggers RD; Gibbs GL; Peddada AV
    Brachytherapy; 2008; 7(1):7-11. PubMed ID: 18299109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
    Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
    Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
    Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N
    Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis.
    Kalakota K; Rakhno E; Pelizzari CA; Jani AB; Liauw SL
    Brachytherapy; 2010; 9(2):131-6. PubMed ID: 19853533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B
    Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
    Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
    Acta Oncol; 2007; 46(7):909-17. PubMed ID: 17917823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
    Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
    Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study.
    Mahmoudieh A; Tremblay C; Beaulieu L; Lachance B; Harel F; Lessard E; Pouliot J; Vigneault E
    Radiother Oncol; 2005 Jun; 75(3):318-24. PubMed ID: 16086913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.